Korro
IPO
Editing RNA to rewrite the future of medicine
- Headquarters
- Cambridge, Massachusetts
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- korrobio.com
- Total Funding
- $155.0M
- Last Round
- $85.0M Private EquityMar 2026
About
Korro Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing a new class of genetic medicines based on editing RNA. By leveraging endogenous RNA editing mechanisms, Korro's platform enables treatment of both rare and highly prevalent diseases. The company's lead program KRRO-110 targets alpha-1 antitrypsin deficiency (AATD). Founded in 2019 out of Atlas Venture, Korro merged with Frequency Therapeutics in 2023 and listed on Nasdaq (KRRO).
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account